Biochemicals

A unique range of over 3000 novel substituted fluoro aromatic compounds functionalised with a variety of synthetically useful reactive groups.

Top of page

Industry News

Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, says AZ.
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us